BioCryst Pharmaceuticals (BCRX - Free Report) closed at $3.55 in the latest trading session, marking a -0.28% move from the prior day. This change lagged the S&P 500's 1.47% gain on the day. At the same time, the Dow added 1.51%, and the tech-heavy Nasdaq gained 1.11%.
Coming into today, shares of the drugmaker had gained 78.89% in the past month. In that same time, the Medical sector gained 22.72%, while the S&P 500 gained 16.09%.
Wall Street will be looking for positivity from BCRX as it approaches its next earnings report date. This is expected to be May 6, 2020. On that day, BCRX is projected to report earnings of -$0.26 per share, which would represent year-over-year growth of 7.14%. Meanwhile, our latest consensus estimate is calling for revenue of $2.71 million, down 54.06% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.97 per share and revenue of $25.32 million. These totals would mark changes of -3.19% and -48.15%, respectively, from last year.
Any recent changes to analyst estimates for BCRX should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.97% higher. BCRX is currently sporting a Zacks Rank of #2 (Buy).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 11, which puts it in the top 5% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
BioCryst Pharmaceuticals (BCRX - Free Report) closed at $3.55 in the latest trading session, marking a -0.28% move from the prior day. This change lagged the S&P 500's 1.47% gain on the day. At the same time, the Dow added 1.51%, and the tech-heavy Nasdaq gained 1.11%.
Coming into today, shares of the drugmaker had gained 78.89% in the past month. In that same time, the Medical sector gained 22.72%, while the S&P 500 gained 16.09%.
Wall Street will be looking for positivity from BCRX as it approaches its next earnings report date. This is expected to be May 6, 2020. On that day, BCRX is projected to report earnings of -$0.26 per share, which would represent year-over-year growth of 7.14%. Meanwhile, our latest consensus estimate is calling for revenue of $2.71 million, down 54.06% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.97 per share and revenue of $25.32 million. These totals would mark changes of -3.19% and -48.15%, respectively, from last year.
Any recent changes to analyst estimates for BCRX should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.97% higher. BCRX is currently sporting a Zacks Rank of #2 (Buy).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 11, which puts it in the top 5% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BCRX - FREE